AbbVie stocks tumble after schizophrenia drug disappoints Monetary TimesAbbVie Inventory Tumbles on Failed Schizophrenia Drug Research. Bristol Myers Jumps. Barron’sBristol Soars 11% As Traders Query AbbVie’s Expensive ‘Mistake’ Investor’s Industry DailyAbbVie Inventory Sinks After Schizophrenia Drug Trials Disappoint InvestopediaAbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials Bloomberg
